Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Toxicol Lett ; 285: 74-80, 2018 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-29305325

RESUMEN

Trastuzumab (Herceptin®), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2+ breast cancer patients. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood. Here we utilized human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. We demonstrate that cardiotoxic effects of ErbB2 inhibition by trastuzumab can be recapitulated only when the cardioprotective effects of ErbB2/4 signaling is observed. We observed no cardioprotective effects of ErbB2/4 signaling without cellular stress (doxorubicin exposure in this study). In addition to neuregulin-1 (NRG-1), we show that heparin-binding epidermal growth factor-like growth factor (HB-EGF) also provides cardioprotective effects for iPS-CMs. Finally, we demonstrate a simple, high-throughput co-culture platform utilizing iPS-CMs and endothelial cells that is capable of detecting trastuzumab-related cardiotoxicity. We conclude that iPS-CMs can recapitulate trastuzumab-related cardiotoxicity, and may be used to elucidate additional modes of toxicity of trastuzumab and related compounds.


Asunto(s)
Antineoplásicos Inmunológicos/toxicidad , Células Madre Pluripotentes Inducidas/efectos de los fármacos , Modelos Biológicos , Miocitos Cardíacos/efectos de los fármacos , Receptor ErbB-2/antagonistas & inhibidores , Trastuzumab/toxicidad , Cardiotoxicidad , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Ensayos Analíticos de Alto Rendimiento , Humanos , Células Madre Pluripotentes Inducidas/citología , Células Madre Pluripotentes Inducidas/enzimología , L-Lactato Deshidrogenasa/metabolismo , Miocitos Cardíacos/citología , Miocitos Cardíacos/enzimología
2.
Tissue Eng Part C Methods ; 23(8): 474-484, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28622076

RESUMEN

Microphysiological systems (MPS), or "organ-on-a-chip" platforms, aim to recapitulate in vivo physiology using small-scale in vitro tissue models of human physiology. While significant efforts have been made to create vascularized tissues, most reports utilize primary endothelial cells that hinder reproducibility. In this study, we report the use of human induced pluripotent stem cell-derived endothelial cells (iPS-ECs) in developing three-dimensional (3D) microvascular networks. We established a CDH5-mCherry reporter iPS cell line, which expresses the vascular endothelial (VE)-cadherin fused to mCherry. The iPS-ECs demonstrate physiological functions characteristic of primary endothelial cells in a series of in vitro assays, including permeability, response to shear stress, and the expression of endothelial markers (CD31, von Willibrand factor, and endothelial nitric oxide synthase). The iPS-ECs form stable, perfusable microvessels over the course of 14 days when cultured within 3D microfluidic devices. We also demonstrate that inhibition of TGF-ß signaling improves vascular network formation by the iPS-ECs. We conclude that iPS-ECs can be a source of endothelial cells in MPS providing opportunities for human disease modeling and improving the reproducibility of 3D vascular networks.


Asunto(s)
Técnicas de Cultivo de Célula/métodos , Células Endoteliales/citología , Células Madre Pluripotentes Inducidas/citología , Neovascularización Fisiológica , Inhibidores de la Angiogénesis/farmacología , Antígenos CD/metabolismo , Cadherinas/metabolismo , Diferenciación Celular/efectos de los fármacos , Línea Celular , Separación Celular , Células Endoteliales/efectos de los fármacos , Humanos , Células Madre Pluripotentes Inducidas/efectos de los fármacos , Microfluídica , Neovascularización Fisiológica/efectos de los fármacos , Fenotipo , Resistencia al Corte , Bibliotecas de Moléculas Pequeñas/farmacología , Factor de Crecimiento Transformador beta/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA